Cachexia decoded: Why diagnosis matters in cancer survival
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-May-2025 11:08 ET (1-May-2025 15:08 GMT/UTC)
Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with advanced cancer. A new study from Japan has revealed that lower cachexia rates, particularly with prevalence less than 40–50%, are linked to shorter overall survival (OS) rates. The study also showed that the diagnostic criteria used for cachexia detection can affect the reported cachexia prevalence.
Some patients being treated with immune checkpoint inhibitors, a type of cancer immunotherapy, develop a dangerous form of heart inflammation called myocarditis. Researchers led by physicians and scientists at the Broad Institute of MIT and Harvard and Massachusetts General Hospital have now uncovered the immune basis of this inflammation. The team identified changes in specific types of immune and stromal cells in the heart that underlie myocarditis and pinpointed factors in the blood that may indicate whether a patient’s myocarditis is likely to lead to death. Appearing in Nature, the results are among the earliest translational findings to come from the Severe Immunotherapy Complications (SIC) Service and Clinical-Translational Research Effort, which is based at Mass General Cancer Center.
Exhaled breath contains chemical clues to what’s going on inside the body, including diseases like lung cancer. And devising ways to sense these compounds could help doctors provide early diagnoses — and improve patients’ prospects. In a study in ACS Sensors, researchers report developing ultrasensitive, nanoscale sensors that in small-scale tests distinguished a key change in the chemistry of the breath of people with lung cancer. November is Lung Cancer Awareness Month.